BIOMAT Database Logo BIOMAT Database Logo

Mutations within the reactive-site region of human pancreatic secretory trypsin inhibitor confer alpha-thrombin and factor Xa inhibitory activities. 1997

T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.

Mutations were introduced into the reactive-site region of human pancreatic secretory trypsin inhibitor (PSTI) to produce thrombin and/or factor Xa inhibitors. All of five mutants showed trypsin inhibitory activity as strong as wild-type PSTI. Moreover, the Arg (P1), Pro-Arg (P2-P1), and Pro-Arg-Ile-Tyr-Asn (P2-P1-P1'-P2'-P3') (bold letters indicated replaced amino acids compared to the wild type) mutants had additional inhibitory activities toward factor Xa, both thrombin and factor Xa, and thrombin, respectively, at 1 x 10(-5) M.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin
D014359 Trypsin Inhibitor, Kazal Pancreatic A secreted KAZAL MOTIF-containing serine peptidase inhibitor that inhibits TRYPSIN. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ). It protects against the trypsin-mediated premature activation of ENZYME PRECURSORS in the PANCREAS. Mutations in the SPINK1 gene are associated with CHRONIC PANCREATITIS. Acidic Pancreatic Trypsin Inhibitor,Kazal Pancreatic Trypsin Inhibitor,Pancreatic Secretory Trypsin Inhibitor, Kazal,Pancreatic Trypsin Secretory Inhibitor, Kazal,Trypsin Inhibitor, Pancreatic Secretory,Inhibitor, Tumor-Associated Trypsin,Pancreatic Secretory Trypsin Inhibitor,SPINK1,Serine Peptidase Inhibitor, Kazal-Type 1,Serine Protease Inhibitor Kazal-Type 1,Trypsin Inhibitor Kazal Pancreatic,Trypsin Inhibitor, Tumor-Associated,Tumor-Associated Trypsin Inhibitor,Serine Peptidase Inhibitor, Kazal Type 1,Serine Protease Inhibitor Kazal Type 1,Trypsin Inhibitor, Tumor Associated,Tumor Associated Trypsin Inhibitor
D016296 Mutagenesis Process of generating a genetic MUTATION. It may occur spontaneously or be induced by MUTAGENS. Mutageneses
D065427 Factor Xa Inhibitors Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor

Related Publications

T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Dissociation of heparin-dependent thrombin and factor Xa inhibitory activities of antithrombin-III by mutations in the reactive site.
April 1993, The Journal of biological chemistry,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Site-directed mutagenesis of human pancreatic secretory trypsin inhibitor.
December 1989, Journal of biochemistry,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Human pancreatic secretory trypsin inhibitor.
January 1976, Methods in enzymology,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
The action of factor Xa, thrombin and trypsin on human factor II.
December 1973, Biochimica et biophysica acta,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Novel factor Xa and plasma kallikrein inhibitory-activities of the second Kunitz-type inhibitory domain of urinary trypsin inhibitor.
February 1994, Thrombosis research,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
The multiplicity of human pancreatic secretory trypsin inhibitor.
September 1985, Journal of biochemistry,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Thrombin, factor Xa, and trypsin in factor X activation.
January 1982, New Istanbul contribution to clinical science,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Thermodynamics and kinetics of the reactive site peptide-bond hydrolysis in bovine pancreatic secretory trypsin inhibitor (Kazal).
August 1973, Biochemistry,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Pancreatic secretory trypsin inhibitor in human Brunner's glands.
February 1995, Journal of gastroenterology,
T Katoh, and M Tamaki, and N Kikuchi, and H Teraoka, and K Nagata, and N Yoshida
Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases.
April 1980, Clinica chimica acta; international journal of clinical chemistry,
Copied contents to your clipboard!